Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levalbuterol hydrochloride.

D A Handley1, J Morley, L Vaickus

  • 1Sepracor, Inc., 111 Locke Drive, Marlborough, MA 01752, USA.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase transitions in the classical simulability of open quantum systems.

Scientific reports·2023
Same author

Editorial: Loneliness in Old Age: An unaddressed Health Problem.

The journal of nutrition, health & aging·2020
Same author

Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Designing Drug Trials for Frailty: ICFSR Task Force 2018.

The Journal of frailty & aging·2018
Same author

Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force.

The Journal of frailty & aging·2018
Same author

Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations.

The journal of nutrition, health & aging·2013
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

Racemic salbutamol contains both active (R)-salbutamol and inactive (S)-salbutamol. Using (R)-salbutamol alone offers improved asthma symptom relief and reduces side effects compared to the racemic mixture.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Immunology

Background:

  • Racemic salbutamol (albuterol) is a common asthma medication activating beta-adrenoceptors.
  • It contains (R)-salbutamol (active) and (S)-salbutamol (inactive).
  • Regular use of racemic salbutamol can lead to decreased efficacy and increased airway responsiveness.

Purpose of the Study:

  • To evaluate the therapeutic advantages of using (R)-salbutamol alone compared to racemic salbutamol.
  • To investigate the differential effects of (R)- and (S)-salbutamol on airway inflammation and responsiveness.

Main Methods:

  • Comparative analysis of bronchodilator responses to (R)-salbutamol and racemic salbutamol in asthma patients.
  • In vitro assessment of the effects of (R)- and (S)-salbutamol on human eosinophil activation.

Related Experiment Videos

  • Evaluation of airway hyperresponsiveness changes with regular use of each formulation.

    • Main Results:

    • (R)-salbutamol demonstrated superior bronchodilator efficacy and protection against bronchoconstrictors compared to racemic salbutamol.
    • (R)-salbutamol at lower doses provided comparable or better efficacy with significantly reduced side effects.
    • (S)-salbutamol was found to augment eosinophil activation and airway hyperresponsiveness, while (R)-salbutamol inhibited these effects.

    Conclusions:

    • Replacing racemic salbutamol with (R)-salbutamol may eliminate adverse effects and enhance asthma management.
    • (R)-salbutamol offers a novel therapeutic approach combining bronchodilation, bronchoprotection, and anti-inflammatory properties.
    • Pharmacokinetic stability of (R)-salbutamol ensures consistent therapeutic outcomes.